Literature DB >> 16563642

Characterization of CB1 cannabinoid receptor immunoreactivity in postmortem human brain homogenates.

M López De Jesús1, J Sallés, J J Meana, L F Callado.   

Abstract

The CB1 cannabinoid receptor (CB1) is the predominant type of cannabinoid receptor in the CNS, in which it displays a unique anatomical distribution and is present at higher densities than most other known seven transmembrane domain receptors. Nevertheless, as with almost all seven transmembrane domain receptors, the tertiary and quaternary structure of this receptor is still unknown. Studies of CB1 in rat cerebral tissue are scarce, and even less is known regarding the expression of CB1 in the human brain. Thus, the aim of the present work was to characterize CB1 expression in membranes from postmortem human brain using specific antisera raised against this protein. Western blot analysis of P1 and P2 fractions, and crude plasma membrane preparations from the prefrontal cortex showed that CB1 migrated as a 60 kDa monomer under reducing conditions. These data were confirmed by blotting experiments carried out with human U373MG astrocytoma cells as a positive control for CB1 expression and wild-type CHO cells as negative control. In addition, when proteins were solubilized in the absence of dithiothreitol, the anti-human CB1 antiserum detected a new band migrating at around 120 kDa corresponding in size to a putative CB1 dimer. This band was sensitive to reducing agents (50 mM dithiothreitol) and showed sodium dodecylsulphate stability, suggesting the existence of disulfide-linked CB1 dimers in the membrane preparations. Important differences in the anatomical distribution of CB1 were observed with regard to that described previously in monkey and rat; in the human brain, CB1 levels were higher in cortex and caudate than in the cerebellum.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16563642     DOI: 10.1016/j.neuroscience.2006.02.024

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  20 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans.

Authors:  Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

3.  Neuromolecular Mechanisms of Cannabis Action.

Authors:  Yousra Adel; Stephen P H Alexander
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Exogenous and endogenous cannabinoids suppress inhibitory neurotransmission in the human neocortex.

Authors:  Flora E Kovacs; Tim Knop; Michal J Urbanski; Ilka Freiman; Thomas M Freiman; Thomas J Feuerstein; Josef Zentner; Bela Szabo
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

5.  Cannabinoid receptor expression in HIV encephalitis and HIV-associated neuropathologic comorbidities.

Authors:  M A Cosenza-Nashat; A Bauman; M-L Zhao; S Morgello; H-S Suh; S C Lee
Journal:  Neuropathol Appl Neurobiol       Date:  2011-08       Impact factor: 8.090

6.  Cannabinoid CB₁ receptor is downregulated in clear cell renal cell carcinoma.

Authors:  Gorka Larrinaga; Begoña Sanz; Itxaro Pérez; Lorena Blanco; María L Cándenas; Francisco M Pinto; Javier Gil; José I López
Journal:  J Histochem Cytochem       Date:  2010-09-17       Impact factor: 2.479

7.  Regulation of cannabinoid CB2 receptor constitutive activity in vivo: repeated treatments with inverse agonists reverse the acute activation of JNK and associated apoptotic signaling in mouse brain.

Authors:  Glòria Salort; María Álvaro-Bartolomé; Jesús A García-Sevilla
Journal:  Psychopharmacology (Berl)       Date:  2017-01-26       Impact factor: 4.530

8.  Development and preliminary validation of a plate-based CB1/CB2 receptor functional assay.

Authors:  K S S Dossou; K P Devkota; P V Kavanagh; J A Beutler; J M Egan; R Moaddel
Journal:  Anal Biochem       Date:  2013-03-07       Impact factor: 3.365

9.  Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment.

Authors:  Leyre Urigüen; M Julia García-Fuster; Luis F Callado; Benito Morentin; Romano La Harpe; Vicent Casadó; Carmen Lluis; Rafael Franco; Jesús A García-Sevilla; J Javier Meana
Journal:  Psychopharmacology (Berl)       Date:  2009-08-04       Impact factor: 4.530

10.  [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor.

Authors:  H Donald Burns; Koen Van Laere; Sandra Sanabria-Bohórquez; Terence G Hamill; Guy Bormans; Wai-si Eng; Ray Gibson; Christine Ryan; Brett Connolly; Shil Patel; Stephen Krause; Amy Vanko; Anne Van Hecken; Patrick Dupont; Inge De Lepeleire; Paul Rothenberg; S Aubrey Stoch; Josee Cote; William K Hagmann; James P Jewell; Linus S Lin; Ping Liu; Mark T Goulet; Keith Gottesdiener; John A Wagner; Jan de Hoon; Luc Mortelmans; Tung M Fong; Richard J Hargreaves
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.